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Abstract
Background: Recent genome-wide association studies (GWAS) have identified many SNPs associated with type 2
diabetes mellitus (T2DM). However, the functional roles for most of the SNPs have not been elucidated. MicroRNAs
(miRNAs) are key regulators of gene expression involved in the development and progression of various diseases
including T2DM. In this study, we investigated whether commonly occurring SNPs modulate miRNA-directed regulation
of gene expression, and whether such SNPs in miRNA-binding sites are associated with the susceptibility for T2DM.
Methods: Genotypes of eleven 3′ untranslated region (UTR) SNPs of seven susceptibility genes for T2DM were
determined in 353 T2DM patients and 448 control subjects. In addition, the interactions of miRNAs with the 3′UTR
in the hepatocyte nuclear factor 1β (HNF1B) gene were investigated using luciferase reporter assays.
Results: One 3′UTR SNP (rs2229295) in the HNF1B gene was significantly associated with T2DM, and the frequency
of an A allele (rs2229295) in T2DM patients was decreased compared with that in controls. Luciferase reporter
assays showed that the SNP (rs2229295) altered the binding of two miRNAs (hsa-miR-214-5p and hsa-miR-550a-5p).
Conclusions: We have detected the interactions of hsa-miR-214-5p/hsa-miR-550a-5p and the 3′UTR SNP of the
HNF1B gene by in vitro luciferase reporter assays, and propose that the binding of such miRNAs regulates the
expression of the HNF1B gene and the susceptibility of T2DM.
Background
Type 2 diabetes mellitus (T2DM) is a common heteroge-
neous and complex disease that is characterized by
hyperglycemia resulting from impaired pancreatic β-cell
function and a decreased action of insulin on target tis-
sues. A combination of multiple genetic and environ-
mental factors is considered to contribute to the
pathogenesis of this disease. Patients with T2DM are at
greater risk of developing cardiovascular diseases, renal
failure, neurological conditions, and retinopathy [1–3]
Recent genome-wide association studies (GWAS) have
successfully identified over 65 susceptibility loci associ-
ated with T2DM and related metabolic traits [4–6].
GWAS have been a powerful approach to identify single
nucleotide polymorphisms (SNPs) associated with dis-
ease risk. However, most of the SNPs in susceptibility
genes for T2DM identified in previous studies were lo-
cated within non-translated regions, such as introns, 3′-
untranslated regions (3′UTRs), and 5′UTRs. Therefore,
functional roles for many of the SNPs in susceptibility
genes have not been elucidated.
MicroRNAs (miRNAs) are endogenous noncoding
RNAs (19–25 nucleotides in length) that induce the trans-
lational repression and degradation of target mRNAs by
complementarily binding to their 3′UTR [7]. By si-
lencing their target gene expression, miRNAs are in-
volved in a variety of biological processes, as well as
the development and progression of human diseases
including cancer and T2DM [8–13]. Previous studies
showed that SNPs within or proximal to miRNA-
binding sites in target genes have the potential to ei-
ther create or destroy binding sites, which affects the
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efficiency of miRNA binding on target sites. Thus,
SNPs in miRNA-binding sites may modulate expres-
sion and protein levels of target genes, and ultimately
contribute to phenotypic variations, including disease
susceptibility and important traits [9–11, 14].
In this study, we investigated whether commonly occur-
ring SNPs modulate miRNA-directed regulation of gene
expression, and whether such SNPs in miRNA-binding
sites are associated with the susceptibility for T2DM.
Methods
Subjects
The participants recruited for this study were Japanese
who underwent a routine medical check-up at a medical
center near the University of Shizuoka. We selected men
under 65 years of age as subjects in this study. The case
subjects with T2DM (n = 353) were diagnosed as T2DM
by physicians according to the World Health Organization
(WHO) diagnostic criteria for T2DM [15]. Of these, 251
T2DM patients (71.1 %) were under oral medication
for diabetes. The control subjects (n = 448) were ran-
domly selected according to the following criteria to
exclude persons with potential glucose intolerance: (1)
fasting plasma glucose levels were under 100 mg/dL
(5.6 mmol/L), and (2) HbA1c levels were under 6.2 %.
All subjects provided written informed consent to par-
ticipate in this study, and the study was approved by
the Ethics Committee of the University of Shizuoka
(Approval No. 17-1)
After overnight fasting, blood was collected from each
subject. The clinical characteristics of the subjects were
determined according to the medical check-up protocol
(Table 1).
DNA analysis
We first selected 20 risk genes for T2DM, which con-
tains 17 risk genes that had been examined the associ-
ation for T2DM in our previous study [16], and three
risk genes (PPARGC1A, IRS2, and SPRY2) [17–19].
These 20 genes were confirmed the association with
T2DM in Asian populations [4, 5]. Next, we searched
SNPs in the miRNA-binding sites in the 3′UTR of
these 20 T2DM risk genes using three online databases:
MirSNP [20, 21], PolymiRTS database 3.0 [22, 23], and
miRNASNP [24, 25]. Finally, we selected 11 SNPs with
minor allele frequency >0.05 in Japanese in the 3′UTR
of seven T2DM susceptible genes (Table 2).
Genomic DNA was isolated from peripheral leuko-
cytes by the phenol extraction method. The genotypes of
the SNPs were determined for each subject using the
PCR-restriction fragment length polymorphism method.
HNF1B 3′UTR reporter gene construction
Two SNPs (rs2229295 C >A, rs1800929 A >G) lie next to
each other in the microRNA binding sites in the 3′UTR
of the hepatocyte nuclear factor 1B (HNF1B) gene. The
HNF1B 3′UTR (920 bp) was amplified using PrimeSTAR®
HS DNA Polymerase (Takara Bio Inc., Otsu, Japan) from
the genomic DNA of the homozygote for major alleles of
the two SNPs (C for rs2229295, A for rs1800929). The pri-
mer sequences are listed in Additional file 1.
The purified PCR product was subcloned into pUC18
vector. We then generated five distinct reporter gene
constructs containing sequences as follows: (1) C
(rs2229295), A (rs1800929), (2) C (rs2229295), G (rs1
800929), (3) A (rs2229295), A (rs1800929), (4) A (rs2
229295), G (rs1800929), and (5) T, C (as a reference;
Table 1 Characteristics of the study subjects
T2DM Control P -value
n = 353 n = 448
Age (years) 54.4 ± 6.5 53.7 ± 5.1 0.12
BMI (kg/m2) 25.0 ± 3.6 23.1 ± 2.6 <0.0001
Glucose (mg/dl)* 155.0 ± 43.2 91.8 ± 4.9 <0.0001
HbA1c (%) 7.7 ± 1.57 5.4 ± 0.34 <0.0001
SBP (mmHg) 126.3 ± 15.6 120.5 ± 16.2 <0.0001
DBP (mmHg) 79.9 ± 11.0 76.8 ± 12.0 0.0002
Total-cholesterol (mg/dl) 212.5 ± 34.7 210.2 ± 31.7 0.33
LDL-cholesterol (mg/dl) 130.8 ± 29.9 129.5 ± 29.9 0.55
HDL-cholesterol (mg/dl) 54.0 ± 15.9 58.4 ± 16.4 0.0001
Triglyceride (mg/dl)* 161.8 ± 145.0 136.3 ± 112.8 0.0001
Obesity/Overweight (BMI ≥ 25) (%) 45.0 23.2 <0.0001
Current smoker (%) 43.7 41.8 0.61
*Statistical test for glucose and triglyceride levels were caluculated on log-transformed values
P-values between T2DM and control groups were caluculated by t-test or χ2 -test
Data are expressed as mean ± SD or percentage
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randomly selected nucleotide sequence), by site-directed
mutagenesis using PrimeSTAR® Mutagenesis Basal Kit
(Takara Bio). The primer sequences used in the site-
directed mutagenesis are listed in Additional file 1.
These inserts were removed by digestion with Sma I
and Hind III, and cloned downstream of the luciferase
gene in a reporter vector; pMIR-REPORT™ Luciferase
(Ambion Inc., Austin, TX, USA). Each construct was
sequenced to confirm the sequence and orientation of
the insert.
Table 2 Associations between T2DM and 3′ UTR SNPs of susceptibility genes for T2DM
Gene SNP Predicted interacting miRNA Genotype T2DM n (%) Control n (%) OR (95%CI) P-value Power
SLC30A8 rs11558471 hsa-miR-1205 AA 130 (37.3) 135 (30.7) 1 (Reference) 0.022 0.78
hsa-miR-1248 AG 168 (48.1) 229 (52.1) 0.78 (0.62–0.96)
hsa-miR-3074-5p GG 51 (14.6) 76(17.3) 0.60 (0.39–0.93)
rs3802178 hsa-miR-1234-3p AA 145 (41.6) 215 (48.4) 1 (Reference) 0.10 0.74
GA 169 (48.4) 187 (42.1) 1.21 (0.96–1.51)
GG 35 (10.0) 42 (9.5) 1.46 (0.93–2.30)
rs2466295 hsa-miR -586 TT 275 (77.9) 341 (76.8) 1 (Reference) 0.67 0.52
TC 71 (20.1) 91 (20.5) 0.94 (0.69–1.27)
CC 7 (2.0) 12 (2.7) 0.88 (0.48–1.60
rs2466293 hsa-miR- 181a-2-3p TT 95 (27.3) 145 (33.2) 1 (Reference) 0.11 0.78
hsa-miR-660-5p TC 181 (52.0) 203 (46.5) 1.19 (0.96–1.47)
hsa-miR-888-3p CC 72 (20.7) 89 (20.4) 1.41 (0.93–2.15)
hsa-miR-1273d
HNF1B rs2229295 hsa-miR214-5p CC 278 (78.7) 308 (68.8) 1 (Reference) 0.004 0.61
hsa-miR550a-5p CA 66 (18.7) 121 (27) 0.66 (0.50–0.88)
hsa-miR550a-3-5p AA 9 (2.6) 19 (4.2) 0.44 (0.25–0.77)
hsa-miR1271-3p
rs1800929 hsa-miR214-5p AA 238 (67.4) 285 (63.6) 1 (Reference) 0.071 0.65
hsa-miR550a-5p AG 100 (28.3) 142 (31.7) 0.79 (0.60–1.02)
hsa-miR550a-3-5p GG 15 (4.3) 21 (4.7) 0.62 (0.37–1.04)
hsa-miR1271-3p
CDC123 rs10951 hsa-miR-145-5p GG 169 (53.5) 249 (60.9) 1 (Reference) 0.027 0.65
hsa-miR-770-5p GA 134 (42.4) 147 (35.9) 1.36 (1.04–1.79)
hsa-miR-4712-5p AA 13 (4.1) 13 (3.2) 1.86 (1.07–3.22)
PPARGC1A rs6821591 hsa-miR-187-3p TT 180 (55.7) 200 (48.7) 1 (Reference) 0.13 0.73
hsa-miR-595 TC 120 (37.2) 180 (43.8) 0.83 (0.65–1.06)
CC 23 (7.1) 31 (7.5) 0.69 (0.42–1.12)
UBE2E2 rs7631705 hsa-miR-888-3p TT 155 (47.8) 165 (42.5) 1 (Reference) 0.018 0.76
hsa-miR-3660 TC 143 (44.1) 170 (43.8) 0.75 (0.59–0.95)
hsa-miR-4526 CC 26 (8.0) 53 (13.7) 0.57 (0.35–0.91)
IRS2 rs2289047 hsa-miR-376c-3p GG 103 (29.6) 141 (32.3) 1 (Reference) 0.22 0.78
GT 163 (46.8) 215 (49.3) 1.14 (0.92–1.40)
TT 82 (23.6) 80 (18.4) 1.29 (0.85–1.96)
SPRY2 rs1644394 hsa-miR-1224-3p TT 199 (57.0) 255 (58.5) 1 (Reference) 0.77 0.69
hsa-miR-1260a TG 124 (35.5) 146 (33.5) 0.97 (0.77–1.22)
hsa-miR-1260b GG 26 (7.5) 35 (8.0) 0.93 (0.59–1.48)
hsa-miR-4733-5p
Odd ratios and P - values were adjusted by age and BMI
Statistically significant P - value after Bonferroni correction was indicated in bold
Power to detect association was estimated under current sample size and minor allele frequency, assuming OR = 1.2 and additive effect
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Luciferase reporter assay
HEK293 cells (a human embryonic kidney cell line) were
cultured in Dulbecco’s Modified Eagle’s medium with
10 % fetal bovine serum. The cells were seeded in 24-
well plates 24 h before transfection. When the cells were
grown to about 80–90 % confluence, the reporter plasmid
(150 ng/well) and miRNA mimics (5 pmol/well) (Bioneer
Inc., Daejeon, Korea) were transfected using Lipofecta-
mine 2000 (Invitrogen, Inc., Carlsbad, CA, USA) accord-
ing to the manufacturer’s instruction. The phRG-TK
vector containing Renilla reniformis luciferase (6.5 ng/
well) (Promega Inc., Madison, WI, USA) was also co-
transfected to standardize transfection efficiency. After
24 h, luciferase activity in cell lysate was measured using
the Dual-Luciferase Reporter Assay System (Promega).
Three independent transfection experiments were per-
formed in triplicate.
Statistical analyses
The associations of genotypes of the eleven 3′ UTR
SNPs in seven T2DM susceptibility genes and T2DM
were examined. The genotype specific odds ratios (ORs)
with 95 % confidence intervals (CIs) and p-values for
T2DM were calculated using logistic regression analysis,
adjusting for age and BMI.
In the luciferase reporter assay, the differences in the
luciferase activity between four kinds of constructs (CA,
CG, AA and AG) were examined by Tukey-Kramer mul-
tiple comparisons test. All statistical analyses were per-
formed using the JMP software package (SAS Institute,
Cary, NC, USA). The power to detect an association be-
tween each SNP and T2DM was estimated under
current sample size and minor allele frequency observed
in this study using “Quanto” [26], assuming OR = 1.2, α
level = 0.05 (one-sided), and additive model.
For association between T2DM and each SNP, p <
0.0045 (0.05/11) was considered as significant by ap-
plying a Bonferroni correction.
Results
We analyzed the relationships between T2DM and geno-
types of eleven 3′UTR SNPs in seven T2DM susceptibil-
ity genes that were previously detected by GWAS. The
genotype distributions of these 11 SNPs were in Hardy-
Weinberg equilibrium (P > 0.05). Table 2 shows the asso-
ciations between T2DM and these SNPs. The ORs and
p-values were adjusted for age and BMI in logistic regres-
sion analysis. One 3′UTR SNP (rs2229295) in the HNF1B
gene was significantly associated with T2DM, and the fre-
quency of CA and AA genotypes of rs2229295 in T2DM
patients was decreased compared with that in controls
(OR = 0.66 (95 % CI: 0.50–0.88), 0.44 (95 % CI: 0.25–0.77),
respectively)) (Table 2). These data indicate that the A al-
lele of 3′UTR SNP (rs2229295) in the HNF1B gene can be
a protective allele for T2DM. The other ten 3′UTR SNPs
in the susceptibility genes were not associated with T2DM.
To investigate the functional impact of the SNP
(rs2229295) in the HNF1B gene, we next searched miR-
NAs whose binding could be affected by the base sub-
stitution due to this SNP (rs2229295) using online
databases (MirSNP, PolymiRTS, and miRNASNP). We
identified four candidate miRNAs whose seed se-
quences correspond with complementary sequences
around the SNP (rs2229295) (Fig. 1). In this region, two
SNPs (rs2229295 C > A, rs1800929 A > G) are located
next to each other. In addition, the seed sequences of
these four miRNA contain complementary sequences
to the minor alleles of two SNPs (A for rs2229295, G
for rs1800929) of the HNF1B gene (Fig. 1).
Next, we tested whether the binding of these four
miRNAs to the 3′UTR of the HNF1B gene was affected
Fig. 1 Predicted miRNAs whose binding are possibly affected by the base substitutions due to SNPs r22229295 and rs1800929. The four miRNAs
were predicted as candidate miRNAs in at least two of three online databases (MirSNP, PolymiRTS, and miRNASNP) [20–25]. Seed sequences of
each miRNA were indicated by bold. The complemetary sequences of 3′UTR of the HNF1B gene were shown by underlined. The red color
showed sites for SNPs (rs2229295 and rs1800929)
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by the two SNPs. We generated four kinds of luciferase
reporter constructs and one reference construct as de-
scribed in Methods (Fig. 2a). The constructs were each
co-transfected in parallel with the four predicted can-
didate miRNA mimics into HEK293 cells, and lucifer-
ase activity was compared. When hsa-miR-214-5p or
hsa-miR-550a-5p mimics were co-transfected with the
reporter construct, significant suppression of luciferase
activity was observed in constructs containing AA or AG
sequences for the two SNPs (rs2229295, rs1800929) com-
pared with the construct containing CA sequence, which
presumably does not bind miRNAs (Fig. 2b). When
the other two miRNA mimics (hsa-miR-550a-3-5p, hsa-
miR-1271-3p) were co-transfected with each reporter con-
struct, there were no differences in luciferase activity
among reporter construct (Additional file 2). Furthermore,
there were no differences in luciferase activities among
reporter constructs when they were transfected into
HEK293 cells without miRNA mimics (Additional file 3).
These data indicate that the substitution of C > A due to
SNP (rs2229295) induces a decrease of luciferase activity.
However, A >G substitution due to SNP (rs1800929) did
not affect luciferase activity. The results of luciferase re-
porter assays showed that the SNP (rs2229295) actually al-
ters the binding of two miRNAs (hsa-miR-214-5p and
hsa-miR-550a-5p), and A allele carrying constructs were
specifically regulated by the two miRNAs, while the adja-
cent SNP (rs1800929) did not affect the binding of the
miRNAs to HNF1B 3′UTR.
Discussion
Previous studies have demonstrated that genetic varia-
tions within miRNA-binding sites could modulate gene
expression and protein levels, and affect phenotypes or
cause disease [8–10]. In this study, we identified an SNP
(rs2229295) in the 3′UTR of the HNF1B gene that could
affect miRNA binding and that was associated with the
risk of T2DM. Two SNPs (rs2229295, rs1800929) lie
next to each other in this region. In silico analysis pre-
dicted that substitutions C > A in rs2229295 and A > G
in rs1800929 create a new potential miRNA-binding site
Fig. 2 Effect of the base substitutions due to SNPs rs2229295 and rs1800929 on miRNA binding. a Schematic representation of reporter constructs
used in the luciferase reporter assay. Plasmid construct containing TC sequence, which was selected randomly, was used as a reference. Major
allele (C for rs2229295) is shown in blue and minor allele (A for rs2229295) is shown in red. b Relative luciferase activity of each reporter
construct. Luciferase activity was normalized to Renilla luciferase levels. Luciferase activities relative to the reference vector (TC vector) are
shown as mean ± S.E. from three independent transfection experiments with triplicate assays. The luciferase activities among four constructs
were compared using the Turkey-Kramer method (*p < 0.05, **p < 0.01)
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in the 3′UTR of the HNF1B gene (Fig. 1). It was ascer-
tained one SNP (C > A in rs2229295) could affect the
binding of two miRNAs (hsa-miR-214-5p, hsa-miR-
550a-5p) by luciferase reporter assay. However, the other
SNP (rs1800929) and two miRNAs (hsa-miR-550a-3-5p,
hsa-miR-1271-3p) did not influence the luciferase activity.
Many potential miRNA target sites can be predicted in 3′
UTRs of many genes by in silico analysis. However, the
binding of miRNAs and target genes have considerable
flexibility and therefore in silico analysis is not sufficient
to define 3′UTR SNPs related to susceptibility of common
diseases.
HNF1B is a homeodomain-containing transcription fac-
tor expressed in multiple tissues, such as the liver, kidney,
pancreas, and genital tract [27, 28]. Mouse studies re-
vealed that HNF1B is a critical regulator of transcriptional
network that controls the specification, growth, and differ-
entiation of the embryonic pancreas [29–31]. In humans,
mutations in the HNF1B gene were described in a mono-
genic form of diabetes, namely maturity-onset diabetes of
the young type 5 (MODY5) [28, 32–35]. Many patients
with MODY5 have impaired insulin secretory responses
to glucose and show progressive loss in basal insulin se-
cretion, although they have various other abnormalities
such as renal cysts, renal impairment, and genital malfor-
mation [28–35].
Some GWAS revealed that several tag SNPs in the
HNF1B gene were associated with the susceptibility of
T2DM, and such associations were well replicated in
many countries [36–38]. However, the SNP (rs 2229295)
that was associated with the risk of T2DM in this study
was not a tag SNP for the HNF1B gene. There is no report
for the association of this SNP (rs 2229295) and T2DM.
We could not observe significant linkage disequilibrium
(LD) between the SNP (rs 2229295) and a tag SNP
(rs7501939) of the HNF1B gene (Additional file 4).
Recently, Kornfeld and colleagues found that obesity-
induced overexpression of miR-802 causes glucose intoler-
ance, impairs insulin signaling, and promotes hepatic
gluconeogenesis in the liver through direct silencing of
HNF1B, and showed an important role for HNF1B in the
control of hepatic insulin sensitivity and glucose metabol-
ism in vivo [39].
We have detected the interactions of hsa-miR-214-5p/
hsa-miR-550a-5p and the 3′UTR of the HNF1B gene by
in vitro luciferase reporter assays, and our results suggest
that binding of hsa-miR-214-5p and hsa-miR-550a-5p
may also regulate the expression of the HNF1B gene. Un-
fortunately, we could not examine the interactions be-
tween such miRNAs and the endogenous HNF1B gene.
Because the genomic sequence of miRNA binding site
of the HNF1B gene in HEK293 cells that we used in this
study is C (rs2229295), this sequence does not bind hsa-
miR-214-5p and hsa-miR-550a-5p. Furthermore, we have
no data as to whether HNF1B mRNA and/or protein
levels in vivo are affected by the genotype of the SNP
(rs2229295).
The miR214 gene is located in an intronic region of the
Dynamin-3 gene on human chromosome 1q24.3, and is
expressed in the liver, kidney, pancreas, and osteoblasts in-
volved in the development of pancreas and bone [40, 41].
The miR-550 gene is located in the intronic region of the
Znrf2 gene on human chromosome 7p14.3, and expressed
in multiple cancers including hepatocellular carcinoma
[42]. However, there is little information regarding the
function and regulation of expression of miR-550 in nor-
mal cells and tissues. We need to know how the expres-
sions of hsa-miR-214-5p and hsa-miR-550a-5p are
regulated in vivo.
In this study, we found the possibility that the binding
of two miRNAs to the 3′UTR of the HNF1B gene pro-
vided the protective effect for T2DM. In most patients
with MODY5, the clinical phenotypes may be related to
loss of function or dominant-negative mechanisms for
HNF1B [28, 32–35]. However, a previous study reported a
mutation that showed a gain-of function phenotype with
increased transcript activity of the HNF1B gene [43]. Im-
portant roles of HNF1B for complex transcriptional net-
works in pancreatic β-cells and hepatocytes have been
established [35, 44, 45]. There is a possibility that the dys-
regulated expression of the HNF1B gene due to nucleotide
changes within the miRNA-binding site would lead to im-
pair transcriptional networks related to HNF1B and the
differences of susceptibility for T2DM. Further experi-
ments are needed to ascertain roles for hsa-miR-214-5p
and hsa-miR-550a-5p and HNF1B-dependent regulation
of insulin secretion, glucose metabolism in vivo.
Conclusions
In this study, we found the 3′UTR SNP (rs2229295) in
the HNF1B gene was associated with the susceptibility
of T2DM. In addition, luciferase reporter assays indicate
that the substitution of C > A due to SNP (rs2229295)
induces the binding of hsa-miR-214-5p/hsa-miR-550a-5p
to the 3′UTR of the HNF1B gene.
There is a possibility that the dysregulated expression
of the HNF1B gene due to nucleotide changes within
miRNA binding site lead the difference of susceptibility
for T2DM.
Additional files
Additional file 1: Table S1. PCR primers used for subcloning and
introduction of nucleotide changes in 3′UTR of HNF1B. (XLSX 11 kb)
Additional file 2: Figure S1. Effect of miRNA (A:hsa-miR-550a-3-5p, B:
hsa-miR1271-3p) binding to reporter constructs. There was no significant
difference in luciferase activities among constructs containing CA, AA, or
AG sequences (for SNP rs2229295 and rs1800929). Luciferase activities
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relative to reference vector (TC vector) were shown as mean ± S.E. from 3
independent transfection experiments with triplicate assays. The comparisons
of luciferase activity among four constructs were using Turkey-Kramer method.
(PDF 10 kb)
Additional file 3: Figure S2. Effect of the base substitutions due to
SNPs (rs2229295 and rs1800929) to luciferase activity. There was no significant
difference in luciferase activity of each reporter constract containing CA, CG,
AA, AG sequence, suggesting that the difference in 3′UTR sequence due to
SNPs (rs2229295 and rs1800929) did not affect the luciferase activity by itself.
Luciferase activity was normalized to Renilla luciferase levels. Luciferase
activities relative to reference vector (TC vector) were shown as mean ± S.E.
from 3 independent transfection experiments with triplicate assays. The
comparison of luciferase activity among four constructs were using Turkey-
Kramer method. (PDF 7 kb)
Additional file 4: Table S2. The pairwise linkage disequilibrium (LD)
values of |D'| (upper) and r2 (lower) (XLSX 11 kb)
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